KR20230118083A - 세포 내 atp 증강제 - Google Patents

세포 내 atp 증강제 Download PDF

Info

Publication number
KR20230118083A
KR20230118083A KR1020237018112A KR20237018112A KR20230118083A KR 20230118083 A KR20230118083 A KR 20230118083A KR 1020237018112 A KR1020237018112 A KR 1020237018112A KR 20237018112 A KR20237018112 A KR 20237018112A KR 20230118083 A KR20230118083 A KR 20230118083A
Authority
KR
South Korea
Prior art keywords
pharmaceutical composition
pharmaceutically acceptable
atp
acceptable salt
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020237018112A
Other languages
English (en)
Korean (ko)
Inventor
미키 히라오카
겐 오카모토
마스하루 히라노
Original Assignee
학교법인 히가시-니뽄-가쿠엔
고쿠리츠다이가쿠호우진 도쿄다이가쿠
닛뽕 케미파 가부시키가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 학교법인 히가시-니뽄-가쿠엔, 고쿠리츠다이가쿠호우진 도쿄다이가쿠, 닛뽕 케미파 가부시키가이샤 filed Critical 학교법인 히가시-니뽄-가쿠엔
Publication of KR20230118083A publication Critical patent/KR20230118083A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
KR1020237018112A 2020-12-08 2021-12-08 세포 내 atp 증강제 Pending KR20230118083A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JPJP-P-2020-203725 2020-12-08
JP2020203725 2020-12-08
PCT/JP2021/045045 WO2022124325A1 (ja) 2020-12-08 2021-12-08 細胞内ａｔｐ増強剤

Publications (1)

Publication Number Publication Date
KR20230118083A true KR20230118083A (ko) 2023-08-10

Family

ID=81973288

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237018112A Pending KR20230118083A (ko) 2020-12-08 2021-12-08 세포 내 atp 증강제

Country Status (8)

Country Link
US (1) US20240051971A1 (https=)
EP (1) EP4260860A4 (https=)
JP (1) JPWO2022124325A1 (https=)
KR (1) KR20230118083A (https=)
CN (2) CN121648131A (https=)
AU (1) AU2021398258A1 (https=)
CA (1) CA3201273A1 (https=)
WO (1) WO2022124325A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025258615A1 (ja) * 2024-06-12 2025-12-18 学校法人日本医科大学 運動機能向上剤、及びそれを含む医薬組成物

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6153281U (https=) 1984-09-13 1986-04-10
WO2018092911A1 (ja) 2016-11-21 2018-05-24 株式会社スタージェン 細胞内ａｔｐ増強剤
JP2018080135A (ja) 2016-11-17 2018-05-24 株式会社スタージェン パーキンソン症状改善用医薬
JP2018118914A (ja) 2017-01-24 2018-08-02 株式会社スタージェン 神経変性疾患の改善用医薬
JP2018135278A (ja) 2017-02-20 2018-08-30 株式会社スタージェン 循環器疾患及び／又はミトコンドリア病の改善用医薬

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2608045B1 (fr) * 1986-12-12 1990-03-02 Chauvin Laboratoires Utilisation d'inhibiteurs de xanthine- oxydase, de piegeurs de radicaux libres oxygenes et de chelateurs du fer pour la fabrication d'une composition pharmaceutique destinee au traitement du glaucome et compositions pharmaceutiques destinees au traitement du glaucome
DK1757610T3 (da) 2004-06-14 2011-08-01 Nippon Chemiphar Co Kondenseret pyrimidinderivat og xanthinoxidaseinhibitor
CN101282934A (zh) * 2005-10-07 2008-10-08 安斯泰来制药株式会社 三芳基羧酸衍生物
ES2884123T3 (es) * 2013-03-15 2021-12-10 Xortx Therapeutics Inc Formulaciones de inhibidores de xantina oxidasa
US10413546B2 (en) * 2015-02-24 2019-09-17 National University Corporation Tottori University Drug for preventing and/or treating dementia
KR102600879B1 (ko) 2015-08-26 2023-11-09 가부시키가이샤 스타젠 세포 내 atp 증강제
JP6937134B2 (ja) * 2016-11-21 2021-09-22 株式会社スタージェン 細胞内ａｔｐ増強剤
TWI780270B (zh) * 2017-11-28 2022-10-11 靜岡縣公立大學法人 固體分散體
JP2021127289A (ja) 2018-04-27 2021-09-02 日本ケミファ株式会社 縮合ピリミジン誘導体
WO2020246528A1 (ja) * 2019-06-04 2020-12-10 日本ケミファ株式会社 痛風又は高尿酸血症の治療薬
CN110156131A (zh) 2019-06-17 2019-08-23 厦门翟苑日用品有限公司 一种幼儿园健康饮用水集中处理器

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6153281U (https=) 1984-09-13 1986-04-10
JP2018080135A (ja) 2016-11-17 2018-05-24 株式会社スタージェン パーキンソン症状改善用医薬
WO2018092911A1 (ja) 2016-11-21 2018-05-24 株式会社スタージェン 細胞内ａｔｐ増強剤
JP2018118914A (ja) 2017-01-24 2018-08-02 株式会社スタージェン 神経変性疾患の改善用医薬
JP2018135278A (ja) 2017-02-20 2018-08-30 株式会社スタージェン 循環器疾患及び／又はミトコンドリア病の改善用医薬

Also Published As

Publication number Publication date
CN116528840A (zh) 2023-08-01
AU2021398258A9 (en) 2024-02-08
CA3201273A1 (en) 2022-06-16
US20240051971A1 (en) 2024-02-15
EP4260860A4 (en) 2024-11-06
CN116528840B (zh) 2026-01-06
WO2022124325A1 (ja) 2022-06-16
EP4260860A1 (en) 2023-10-18
CN121648131A (zh) 2026-03-13
JPWO2022124325A1 (https=) 2022-06-16
WO2022124325A8 (ja) 2023-05-11
AU2021398258A1 (en) 2023-07-06

Similar Documents

Publication Publication Date Title
JP2021059551A (ja) フェニルアミノピリミジン誘導体を含む医薬組成物
EP1849830B1 (en) Finely divided composition containing poorly water soluble substance
US11234984B2 (en) Solid dispersion
JP2025061775A (ja) 痛風又は高尿酸血症の治療薬
CN116528840B (zh) 细胞内atp增强剂
AU2009337766B2 (en) Pharmaceutical formulation of nanonised fenofibrate
JP6903252B2 (ja) キサンチンオキシダーゼ阻害剤含有腸溶性製剤
HK40073463B (en) Therapeutic for gout or hyperuricemia
HK40073463A (en) Therapeutic for gout or hyperuricemia
WO2025258615A1 (ja) 運動機能向上剤、及びそれを含む医薬組成物

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20230526

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20241129

Comment text: Request for Examination of Application